S&P 500   3,168.80 (+0.01%)
DOW   28,135.38 (+0.01%)
QQQ   207.19 (+0.33%)
AAPL   275.15 (+1.36%)
FB   194.11 (-1.34%)
MSFT   154.53 (+0.84%)
GOOGL   1,346.87 (-0.12%)
AMZN   1,760.94 (+0.03%)
CGC   20.68 (-2.13%)
NVDA   223.99 (-0.04%)
MU   51.20 (+0.45%)
BABA   204.91 (+0.20%)
GE   11.34 (-0.87%)
TSLA   358.39 (-0.36%)
T   38.26 (-0.23%)
AMD   41.15 (-3.38%)
ACB   2.63 (+1.15%)
F   9.23 (-0.97%)
PRI   136.56 (+0.04%)
NFLX   298.50 (+0.02%)
BAC   34.44 (-0.69%)
GILD   65.77 (-2.75%)
DIS   146.38 (-0.93%)
S&P 500   3,168.80 (+0.01%)
DOW   28,135.38 (+0.01%)
QQQ   207.19 (+0.33%)
AAPL   275.15 (+1.36%)
FB   194.11 (-1.34%)
MSFT   154.53 (+0.84%)
GOOGL   1,346.87 (-0.12%)
AMZN   1,760.94 (+0.03%)
CGC   20.68 (-2.13%)
NVDA   223.99 (-0.04%)
MU   51.20 (+0.45%)
BABA   204.91 (+0.20%)
GE   11.34 (-0.87%)
TSLA   358.39 (-0.36%)
T   38.26 (-0.23%)
AMD   41.15 (-3.38%)
ACB   2.63 (+1.15%)
F   9.23 (-0.97%)
PRI   136.56 (+0.04%)
NFLX   298.50 (+0.02%)
BAC   34.44 (-0.69%)
GILD   65.77 (-2.75%)
DIS   146.38 (-0.93%)
S&P 500   3,168.80 (+0.01%)
DOW   28,135.38 (+0.01%)
QQQ   207.19 (+0.33%)
AAPL   275.15 (+1.36%)
FB   194.11 (-1.34%)
MSFT   154.53 (+0.84%)
GOOGL   1,346.87 (-0.12%)
AMZN   1,760.94 (+0.03%)
CGC   20.68 (-2.13%)
NVDA   223.99 (-0.04%)
MU   51.20 (+0.45%)
BABA   204.91 (+0.20%)
GE   11.34 (-0.87%)
TSLA   358.39 (-0.36%)
T   38.26 (-0.23%)
AMD   41.15 (-3.38%)
ACB   2.63 (+1.15%)
F   9.23 (-0.97%)
PRI   136.56 (+0.04%)
NFLX   298.50 (+0.02%)
BAC   34.44 (-0.69%)
GILD   65.77 (-2.75%)
DIS   146.38 (-0.93%)
S&P 500   3,168.80 (+0.01%)
DOW   28,135.38 (+0.01%)
QQQ   207.19 (+0.33%)
AAPL   275.15 (+1.36%)
FB   194.11 (-1.34%)
MSFT   154.53 (+0.84%)
GOOGL   1,346.87 (-0.12%)
AMZN   1,760.94 (+0.03%)
CGC   20.68 (-2.13%)
NVDA   223.99 (-0.04%)
MU   51.20 (+0.45%)
BABA   204.91 (+0.20%)
GE   11.34 (-0.87%)
TSLA   358.39 (-0.36%)
T   38.26 (-0.23%)
AMD   41.15 (-3.38%)
ACB   2.63 (+1.15%)
F   9.23 (-0.97%)
PRI   136.56 (+0.04%)
NFLX   298.50 (+0.02%)
BAC   34.44 (-0.69%)
GILD   65.77 (-2.75%)
DIS   146.38 (-0.93%)
Log in

NYSE:ELAN - Elanco Animal Health Stock Price, Forecast & News

$27.78
+0.30 (+1.09 %)
(As of 12/13/2019 04:00 PM ET)
Today's Range
$27.30
Now: $27.78
$27.78
50-Day Range
$25.57
MA: $26.99
$27.87
52-Week Range
$25.25
Now: $27.78
$35.46
Volume3.11 million shs
Average Volume5.17 million shs
Market Capitalization$10.36 billion
P/E Ratio23.54
Dividend YieldN/A
Beta0.71
Elanco Animal Health Incorporated, an animal health company, develops, manufactures, and markets products for companion and food animals. The company offers companion animal disease prevention products, such as parasiticide products that protect pets from worms, fleas, and ticks; companion animal therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications; vaccines, nutritional enzymes, and animal-only antibiotics; and a range of food animal products used in ruminant and swine production. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
CUSIPN/A
CIKN/A
Phone877-352-6261

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$3.07 billion
Cash Flow$2.06 per share
Book Value$14.22 per share

Profitability

Net Income$86.50 million

Miscellaneous

Employees5,590
Market Cap$10.36 billion
Next Earnings Date2/5/2020 (Estimated)
OptionableOptionable

Receive ELAN News and Ratings via Email

Sign-up to receive the latest news and ratings for ELAN and its competitors with MarketBeat's FREE daily newsletter.


Elanco Animal Health (NYSE:ELAN) Frequently Asked Questions

What is Elanco Animal Health's stock symbol?

Elanco Animal Health trades on the New York Stock Exchange (NYSE) under the ticker symbol "ELAN."

How were Elanco Animal Health's earnings last quarter?

Elanco Animal Health (NYSE:ELAN) released its earnings results on Wednesday, November, 6th. The company reported $0.30 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.26 by $0.04. The company had revenue of $771.30 million for the quarter, compared to the consensus estimate of $765.85 million. Elanco Animal Health had a net margin of 3.04% and a return on equity of 7.79%. The company's revenue was up 1.3% compared to the same quarter last year. During the same period in the prior year, the company posted $0.29 EPS. View Elanco Animal Health's Earnings History.

When is Elanco Animal Health's next earnings date?

Elanco Animal Health is scheduled to release their next quarterly earnings announcement on Wednesday, February 5th 2020. View Earnings Estimates for Elanco Animal Health.

What guidance has Elanco Animal Health issued on next quarter's earnings?

Elanco Animal Health issued an update on its FY19 earnings guidance on Wednesday, November, 6th. The company provided earnings per share (EPS) guidance of $1.04-1.08 for the period, compared to the Thomson Reuters consensus EPS estimate of $1.08. The company issued revenue guidance of $3.07-3.085 billion, compared to the consensus revenue estimate of $3.10 billion.

What price target have analysts set for ELAN?

10 analysts have issued 1 year target prices for Elanco Animal Health's shares. Their forecasts range from $28.00 to $37.00. On average, they expect Elanco Animal Health's stock price to reach $32.59 in the next year. This suggests a possible upside of 17.3% from the stock's current price. View Analyst Price Targets for Elanco Animal Health.

What is the consensus analysts' recommendation for Elanco Animal Health?

10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Elanco Animal Health in the last year. There are currently 7 hold ratings and 3 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Elanco Animal Health.

Has Elanco Animal Health been receiving favorable news coverage?

Media stories about ELAN stock have trended positive this week, according to InfoTrie Sentiment Analysis. InfoTrie identifies positive and negative press coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Elanco Animal Health earned a news sentiment score of 2.1 on InfoTrie's scale. They also gave news stories about the company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the stock's share price in the near term. View News Stories for Elanco Animal Health.

Are investors shorting Elanco Animal Health?

Elanco Animal Health saw a drop in short interest in November. As of November 29th, there was short interest totalling 13,490,000 shares, a drop of 6.8% from the November 14th total of 14,480,000 shares. Based on an average daily trading volume, of 3,690,000 shares, the days-to-cover ratio is currently 3.7 days. Currently, 3.6% of the company's stock are sold short. View Elanco Animal Health's Current Options Chain.

Who are some of Elanco Animal Health's key competitors?

What other stocks do shareholders of Elanco Animal Health own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Elanco Animal Health investors own include NVIDIA (NVDA), Home Depot (HD), CVS Health (CVS), Alibaba Group (BABA), Walt Disney (DIS), Honeywell International (HON), Amgen (AMGN), Bank of America (BAC), AT&T (T) and UnitedHealth Group (UNH).

Who are Elanco Animal Health's key executives?

Elanco Animal Health's management team includes the folowing people:
  • Mr. Jeffrey N. Simmons, Pres, CEO & Director (Age 52)
  • Mr. Todd S. Young, Exec. VP & CFO (Age 47)
  • Mr. David S. Kinard, Exec. VP of HR (Age 52)
  • Ms. Sarena S. Lin, Exec. VP of Elanco USA, Corp. Strategy & Global Marketing (Age 48)
  • Mr. David Alan Urbanek, Exec. VP of Manufacturing & Quality (Age 53)

When did Elanco Animal Health IPO?

(ELAN) raised $1.4 billion in an IPO on Thursday, September 20th 2018. The company issued 62,900,000 shares at a price of $20.00-$23.00 per share. Goldman Sachs, J.P. Morgan and Morgan Stanley served as the underwriters for the IPO and Barclays, BNP PARIBAS, BofA Merrill Lynch, Citigroup, Credit Suisse, Deutsche Bank Securities, Evercore ISI, Cowen, Academy Securities, Drexel Hamilton, Mischler Financial Group, Ramirez and The Williams Capital Group were co-managers.

Who are Elanco Animal Health's major shareholders?

Elanco Animal Health's stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Massachusetts Financial Services Co. MA (4.10%), State Street Corp (2.62%), TimesSquare Capital Management LLC (0.42%), California Public Employees Retirement System (0.39%), Sumitomo Mitsui Trust Holdings Inc. (0.38%) and Krensavage Asset Management LLC (0.24%). Company insiders that own Elanco Animal Health stock include David Alan Urbanek, Dawei Li, Deborah Turner Kochevar, Jeffrey N Simmons, John P Bilbrey, Lawrence Erik Kurzius, Michael J Harrington, Michael-Bryant Hicks, R David Hoover, Ramiro Martin Cabral and Todd S Young. View Institutional Ownership Trends for Elanco Animal Health.

Which institutional investors are selling Elanco Animal Health stock?

ELAN stock was sold by a variety of institutional investors in the last quarter, including Massachusetts Financial Services Co. MA, Pictet Asset Management Ltd., First Trust Advisors LP, TimesSquare Capital Management LLC, Nippon Life Global Investors Americas Inc., Voya Investment Management LLC, State of New Jersey Common Pension Fund D and Daiwa Securities Group Inc.. View Insider Buying and Selling for Elanco Animal Health.

Which institutional investors are buying Elanco Animal Health stock?

ELAN stock was acquired by a variety of institutional investors in the last quarter, including State Street Corp, Vantage Investment Partners LLC, Sumitomo Mitsui Trust Holdings Inc., Millennium Management LLC, Sector Gamma AS, General American Investors Co. Inc., California Public Employees Retirement System and Cullen Frost Bankers Inc.. Company insiders that have bought Elanco Animal Health stock in the last two years include David Alan Urbanek, Dawei Li, Deborah Turner Kochevar, Jeffrey N Simmons, John P Bilbrey, Lawrence Erik Kurzius, Michael J Harrington, Michael-Bryant Hicks, R David Hoover, Ramiro Martin Cabral and Todd S Young. View Insider Buying and Selling for Elanco Animal Health.

How do I buy shares of Elanco Animal Health?

Shares of ELAN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Elanco Animal Health's stock price today?

One share of ELAN stock can currently be purchased for approximately $27.78.

How big of a company is Elanco Animal Health?

Elanco Animal Health has a market capitalization of $10.36 billion and generates $3.07 billion in revenue each year. The company earns $86.50 million in net income (profit) each year or $1.18 on an earnings per share basis. Elanco Animal Health employs 5,590 workers across the globe.View Additional Information About Elanco Animal Health.

What is Elanco Animal Health's official website?

The official website for Elanco Animal Health is http://www.elanco.com/.

How can I contact Elanco Animal Health?

Elanco Animal Health's mailing address is 2500 INNOVATION WAY, GREENFIELD IN, 46140. The company can be reached via phone at 877-352-6261.


MarketBeat Community Rating for Elanco Animal Health (NYSE ELAN)

Community Ranking:  2.2 out of 5 (star star)
Outperform Votes:  83 (Vote Outperform)
Underperform Votes:  108 (Vote Underperform)
Total Votes:  191
MarketBeat's community ratings are surveys of what our community members think about Elanco Animal Health and other stocks. Vote "Outperform" if you believe ELAN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ELAN will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 12/13/2019 by MarketBeat.com Staff

Featured Article: Quick Ratio

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel